Background: We aimed to test the diagnostic and prognostic ability of H-ficolin, an initiator of the lectin pathway of the complement system, for functionally relevant coronary artery disease (fCAD), and explore its determinants.
Methods: The presence of fCAD was adjudicated using myocardial perfusion imaging single-photon emission tomography and coronary angiography. H-ficolin levels were measured by a sandwich-type immunoassay at rest, peak stress-test, and 2 h after stress-test. Cardiovascular death and non-fatal myocardial infarction were assessed during 5-year follow-up.
Results: Among 1,571 patients (32.3 % women), fCAD was detected in 462 patients (29.4 %). H-ficolin concentration at rest was 18.6 (15.3-21.8) µg/ml in patients with fCAD versus 17.8 (15.4-21.5) µg/ml, p = 0.33, in patients without fCAD, resulting in an AUC of 0.53 (95 %CI 0.48-0.56). During follow-up, 107 patients (6.8 %) had non-fatal myocardial infarction and 99 patients (6.3 %) experienced cardiovascular death. In Cox regression analysis, H-ficolin was not a predictor of events in the overall cohort. Subgroup analysis suggested a potential link between H-ficolin and non-fatal myocardial infarction in patients without fCAD (adjusted HR 1.03, 95 % CI 1.02-1.15, p = 0.005). H-ficolin concentration showed a weak positive correlation with systolic (r = 0.069, p < 0.001) and diastolic blood pressure (r = 0.111, p < 0.001).
Conclusion: H-ficolin concentration did not have diagnostic and/or prognostic value in patients referred for fCAD work-up.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cca.2023.117582 | DOI Listing |
Vasa
January 2025
Department of Vascular Diseases, University Medical Centre Ljubljana, Slovenia.
Our aim was to evaluate the prognostic value of detectable high-sensitivity cardiac troponin I (hs-cTnI) and ischaemia-modified albumin (IMA) in predicting all-cause death or non-fatal ischaemic events in patients with PAD after endovascular revascularisation of the lower limbs. Patients who underwent successful endovascular revascularisation for chronic limb-threatening ischaemia (CLTI) or disabling intermittent claudication (IC) were prospectively included. Pre-procedural levels of hs-cTnI and IMA were measured, and patients were followed for one year for the occurrence of the composite outcome of all-cause death, non-fatal myocardial infarction, new-onset angina, non-fatal ischaemic stroke, transient ischaemic attack, or progression of PAD.
View Article and Find Full Text PDFJ Cardiovasc Comput Tomogr
January 2025
British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, United Kingdom; Edinburgh Imaging, University of Edinburgh, United Kingdom. Electronic address:
Background: Diabetes mellitus is an established cardiovascular risk factor. We assessed the impact of diabetes mellitus on quantitative plaque and long-term outcomes in patients with and without diabetes mellitus in the Scottish COmputed Tomography of the HEART (SCOT-HEART) trial.
Methods: Coronary artery calcium (CAC) was assessed on non-contrast computed tomography (CT).
Eur J Med Res
January 2025
West China School of Nursing, Sichuan University, Chengdu, 610041, Sichuan, China.
Background: Stroke is an important contributor to disability and death globally. Hypertension is a main risk factor for recurrent stroke in patients with ischemic and hemorrhagic stroke or transient ischemic attack. Higher systolic blood pressure, diastolic blood pressure, pulse pressure and mean arterial pressure at admission are independently associated with the risk of stroke recurrence.
View Article and Find Full Text PDFAm J Cardiol
January 2025
Cardiology Division, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Baim Institute for Clinical Research, Boston, MA, USA. Electronic address:
There are limited tools available to predict the long-term prognosis of persons with coronary chronic total occlusions (CTO). A previously-described blood biomarker panel to predict cardiovascular (CV) events was evaluated in patients with CTO. From 1251 patients in the CASABLANCA study, 241 participants with a CTO were followed for an average of 4 years for occurrence of major adverse CV events (MACE, CV death, non-fatal myocardial infarction or stroke) and CV death/heart failure (HF) hospitalization.
View Article and Find Full Text PDFObjective: Evaluating the change trajectories of triglyceride-glucose (TyG) index calculated after multiple tests in elderly heart failure (HF) patients may have clinical implications for predicting long-term adverse cardiovascular events (MACEs).
Methods: This retrospective study included 1184 elderly HF (LVEF ≥50%) patients with diabetes admitted to our center between January 2015 and January 2020. Based on the multiple TyG levels detected during the exposure period with annual measurements, three distinct TyG trajectories were determined using latent mixture modeling: low-stable group (TyG index <8.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!